Gastric Cancer Market Insights, Epidemiology, and Market Forecast 2030

(Albany, US) DelveInsight ha s launched a new report Gastric Cancer Market

DelveInsight’s Gastric Cancer Market Insights, Epidemiology, and Market Forecast-2030  report delivers an in-depth understanding of the Gastric Cancer, historical and forecasted epidemiology as well as the Gastric Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Gastric Cancer market report provides current treatment practices, emerging drugs, Gastric Cancer market share of the individual therapies, current and forecasted Gastric Cancer market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Gastric Cancer treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

 

Click Here For Free Sample Page:- https://www.delveinsight.com/sample-request/gastric-cancer-market

Gastric Cancer Market Outlook

The Gastric Cancer market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Gastric Cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Gastric Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Gastric Cancer market in 7MM is expected to change in the study period 2017-2030

KEY FACT FROM THE REPORT

• Approximately 0.9% of men and women are diagnosed with Gastric Cancer at some point during their lifetime, based on 2014-2016 data.
• The number of new cases of Gastric Cancer and deaths was 7.4/100,000 men and women/year, and 3.1/100,000 men and women/year, respectively. These rates are age-adjusted and based on cases and deaths in 2012–2016.
• In 2016, an estimated 113,054 people were living with Gastric Cancer in the United States.

 

MAJOR KEY PLAYERS OF THE REPORT

• Innovent Biologics
• RemeGen Co.
• Surface Oncology

 

NAME OF DRUGS COVERED IN THE REPORT

• IBI308
• RC48
• SRF617

 

Table of content

1. Key Insights

2. Executive Summary of Gastric Cancer

3. Competitive Intelligence Analysis for Gastric Cancer

4. Gastric Cancer Market Overview at a Glance

4.1. Gastric Cancer Market Share (%) Distribution in 2017

4.2. Gastric Cancer Total Market Share (%) Distribution in 2030

5. Gastric Cancer: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. Gastric Cancer Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Gastric Cancer Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Gastric Cancer Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Gastric Cancer Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Gastric Cancer Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Gastric Cancer Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Gastric Cancer Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Gastric Cancer Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Gastric Cancer Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Gastric Cancer Treatment and Management

8.2. Gastric Cancer Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Gastric Cancer Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

13. Gastric Cancer: Seven Major Market Analysis

13.1. Key Findings

13.2. Gastric Cancer Market Size in 7MM

13.3. Gastric Cancer Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Gastric Cancer Total Market Size in the United States

15.1.2. Gastric Cancer Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Gastric Cancer Total Market Size in Germany

15.3.2. Gastric Cancer Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Gastric Cancer Total Market Size in France

15.4.2. Gastric Cancer Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Gastric Cancer Total Market Size in Italy

15.5.2. Gastric Cancer Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Gastric Cancer Total Market Size in Spain

15.6.2. Gastric Cancer Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Gastric Cancer Total Market Size in the United Kingdom

15.7.2. Gastric Cancer Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Gastric Cancer Total Market Size in Japan

15.8.3. Gastric Cancer Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Gastric Cancer

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Related Reports

• Gastric Cancer – Epidemiology Forecast to 2030
• Gastric Ulcers – Epidemiology Forecast to 2030

ABOUT DELVEINSIGHT 

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.

CONTACT US:

Shruti Thakur
[email protected]
+91-9650213330
DelveInsight